BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22020023)

  • 1. Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas.
    Paralkar VR; Nasta SD; Morrissey K; Smith J; Vassilev P; Martin ME; Goldstein SC; Loren A; Rook AH; Kim EJ; Porter DL
    Bone Marrow Transplant; 2012 Jul; 47(7):940-5. PubMed ID: 22020023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma.
    Cudillo L; Cerretti R; Picardi A; Mariotti B; De Angelis G; Cantonetti M; Postorino M; Ceresoli E; De Santis G; Nasso D; Pisani F; Scala E; Di Piazza F; Lanti A;
    Ann Hematol; 2018 Jun; 97(6):1041-1048. PubMed ID: 29442161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
    Shimoni A; Nagler A
    Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
    Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
    Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
    Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role for hemopoietic stem-cell transplantation in CTCL?
    Dearden C
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):24-8. PubMed ID: 17474356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).
    Gaudio F; Mazza P; Carella AM; Mele A; Palazzo G; Pisapia G; Carluccio P; Pastore D; Cascavilla N; Specchia G; Pavone V
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):35-40. PubMed ID: 30293754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.
    Delioukina M; Zain J; Palmer JM; Tsai N; Thomas S; Forman S
    Bone Marrow Transplant; 2012 Jan; 47(1):65-72. PubMed ID: 21358679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
    Duvic M; Donato M; Dabaja B; Richmond H; Singh L; Wei W; Acholonu S; Khouri I; Champlin R; Hosing C
    J Clin Oncol; 2010 May; 28(14):2365-72. PubMed ID: 20351328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and Sézary syndrome: a concise review.
    Johnson WT; Mukherji R; Kartan S; Nikbakht N; Porcu P; Alpdogan O
    Chin Clin Oncol; 2019 Feb; 8(1):12. PubMed ID: 30525754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation.
    Herbert KE; Spencer A; Grigg A; Ryan G; McCormack C; Prince HM
    Bone Marrow Transplant; 2004 Sep; 34(6):521-5. PubMed ID: 15286686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic stem cell transplantation for lymphoma.
    Dean RM; Bishop MR
    Clin Lymphoma; 2004 Mar; 4(4):238-49. PubMed ID: 15072616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma.
    Gibson JF; Alpdogan O; Subtil A; Girardi M; Wilson LD; Roberts K; Foss F
    J Am Acad Dermatol; 2015 Jun; 72(6):1010-5.e5. PubMed ID: 25981001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.
    Zain J; Palmer JM; Delioukina M; Thomas S; Tsai NC; Nademanee A; Popplewell L; Gaal K; Senitzer D; Kogut N; O'Donnell M; Forman SJ
    Leuk Lymphoma; 2011 Aug; 52(8):1463-73. PubMed ID: 21699453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution.
    Hosing C; Bassett R; Dabaja B; Talpur R; Alousi A; Ciurea S; Popat U; Qazilbash M; Shpall EJ; Oki Y; Nieto Y; Pinnix C; Fanale M; Maadani F; Donato M; Champlin R; Duvic M
    Ann Oncol; 2015 Dec; 26(12):2490-5. PubMed ID: 26416896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma.
    Cyrenne BM; Gibson JF; Subtil A; Girardi M; Isufi I; Seropian S; Foss F
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e85-e93. PubMed ID: 29223388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.